Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Sandhill Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$10,221,604

982 payments

Through program year 2025, Sandhill Research, LLC is reported as receiving $10,221,604 in research payments, across 982 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $4,808,300 225
2024 Research $341,328 339
2023 Research $365,245 78
2022 Research $2,252,805 141
2021 Research $2,343,222 196
2020 Research $110,705 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Sanofi Pasteur Inc. $4,675,466 133 payments
  2. Janssen Research & Development, LLC $4,175,211 131 payments
  3. Janssen Pharmaceuticals, Inc $591,223 83 payments
  4. Incyte Corporation $377,693 405 payments
  5. Avanir Pharmaceuticals, Inc. $149,664 31 payments
  6. Teva Pharmaceuticals USA, Inc. $97,765 24 payments
  7. Integrative Research Laboratories Sweden AB $71,667 11 payments
  8. Alnylam Pharmaceuticals Inc. $70,904 30 payments
  9. Novo Nordisk AS $9,262 132 payments
  10. Swing Therapeutics, Inc. $2,750 2 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults $4,051,951 124 payments
  2. A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older $1,833,173 34 payments
  3. A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older $1,441,939 33 payments
  4. A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older $1,335,311 42 payments
  5. A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older $591,223 83 payments
  6. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $227,790 303 payments
  7. 17-Avp-786-205 $129,486 25 payments
  8. A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults $103,826 2 payments
  9. A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy $76,500 9 payments
  10. Irl790c005 $71,667 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record